RAB5A and bone metastasis: Our findings expand the knowledge of biological features, which include concomitant overexpression of Rab5a, ET-1/ETAR receptor and SPARC, to identify the group of breast cancer patients with high risk of bone metastasis [17,38], who are suitable for local postoperative radiation therapy and for observational studies.